Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Rheumatology International
Published in: Rheumatology International 8/2007

01-06-2007 | Case Report

Beneficial effect of treatment with cyclosporin A in a case of refractory antisynthetase syndrome

Authors: Magdalena Jankowska, Barbara Butto, Alicja Dębska-Ślizień, Bolesław Rutkowski

Published in: Rheumatology International | Issue 8/2007

Login to get access

Abstract

We report a case of idiopathic inflammatory myopathy accompanied with the presence of anti-Jo1 antibodies and complicated by diffuse parenchymal lung disease (antisynthetase syndrome). Efficacy of different therapeutic agents, including corticosteroids, cyclophosphamide and cyclosporin A, is described. We present beneficial effect of cyclosporin A and corticosteroids regimen, and confirm no benefits of plasmapheresis. An interesting association of the disease onset with toxoplasmosis infection is discussed and difficulties regarding diagnosis of cardiac involvement are addressed. We also review other case reports of this rare disorder of poor prognosis.
Literature
1.
Oddis CV, Rider LG, Reed AM, Ruperto N, Brunner HI, Koneru B, Feldman BM, Giannini EH, Miller FW (2005) International consensus guidelines for trials of therapies in the idiopathic inflammatory myopathies. Arthritis Rheum 9:2607–2615CrossRef
2.
3.
Fathi M, Dastmalchi M, Rasmussen E, Lundberg IE, Torling G (2004) Interstitial lung disease, a common manifestation of newly diagnosed polymyositis and dermatomyositis. Ann Rheum Dis 3:297–301CrossRef
4.
Kalenian M, Zweiman B (1997) Inflammatory myopathy, bronchiolitis obliterans/organizing pneumonia, and anti-Jo-1 antibodies—an interesting association. Clin Diagn Lab Immunol 2:236–240
5.
Schmidt WA, Wetzel W, Friedlander R, Lange R, Sorensen HF, Lichey HJ, Genth E, Mierau R, Gromnica-Ihle E (2000) Clinical and serological aspects of patients with anti-Jo-1 antibodies—an evolving spectrum of disease manifestations. Clin Rheumatol 5:371–377CrossRef
6.
Gabbay E, Tarala R, Will R, Carroll G, Adler B, Cameron D, Lake FR (1997) Interstitial lung disease in recent onset rheumatoid arthritis. Am J Respir Crit Care Med 156:528–535PubMed
7.
Ponyi A, Constantin T, Danko K (2004) Antiphospholipid and antisynthetase syndrome in a patient with polymyositis-rheumatoid arthritis overlap. Clin Rheumatol 4:371–372
8.
Bohan A, Peter JB (1975) Polymyositis and dermatomyositis. N Engl J Med 8:403–407CrossRef
9.
Jorizzo JL (2002) Dermatomyositis: practical aspects. Arch Dermatol 38:114–116CrossRef
10.
Akira M, Hara H, Sakatani M (1999) Interstitial lung disease in association with polymyositis-dermatomyositis: long-term follow-up CT evaluation in seven patients. Radiology 2:333–338
11.
Oddis CV (2000) Current approach to the treatment of polymyositis and dermatomyositis. Curr Opin Rheumatol 12:492–497PubMedCrossRef
12.
Mosca M, Neri R, Pasero G, Bombardieri S (2000) Treatment of the idiopathic inflammatory myopathies: a retrospective analysis of 63 Caucasian patients longitudinally followed at a single center. Clin Exp Rheumatol 4:451–456
13.
Marie I, Hachulla E, Cherin P, Dominique S, Hatron PY, Hellot MF, Devulder B, Herson S, Levesque H, Courtois H (2002) Interstitial lung disease in polymyositis and dermatomyositis. Arthritis Rheum 6:614–622CrossRef
14.
Aoun NY, Velez E, Aggarwal A, Hayes GB, Kenney LA (2004) Fatal acute interstitial pneumonitis complicating polymyositis in a 41-year-old man. Respir Care 12:1515–1521
15.
Schinohara T, Hidaka T, Matsuki Y, Ishizuka T, Takamizawa M, Kawakami M, Kikuma H, Suzuki K, Nakamura H (1997) Rapidly progressive interstitial lung disease associated with dermatomyositis responding to intravenous cyclophosphamide pulse therapy. Intern Med 7:519–523
16.
Tomsik M, Sifrer F (2000) Acute respiratory distress syndrome in a polymyositis patient with anti-Jo1 antibody. Wien Klin Wochenschr 25:728–731
17.
Yoshida T, Koga H, Saitoh F, Sakamoto M, Harada M, Yoshida H, Sakisaka S, Sata M (1999) Pulse intravenous cyclophosphamide treatment for steroid-resistant interstitial pneumonitis associated with polymyositis. Intern Med 9:733–738
18.
Baer AN (2006) Advances in the therapy of idiopathic inflammatory myopathies. Curr Opin Rheumatol 3:236–241CrossRef
19.
Lambotte O, Kotb R, Maigne G, Blanc FX, Goujard C, Delfraissy JF (2005) Efficacy of rituximab in refractory polymyositis. J Rheumatol 7:1369–1370
20.
Lange U, Piegsa M, Muller-Ladner U, Strunk J (2006) Anti-Jo-1 antibody positive polymyositis-successful therapy with leflunomide. Autoimmunity 3:261–264CrossRef
21.
Danieli MG, Malcangi G, Palmieri C, Salvi A, Piani M, Danieli G (2002) Cyclosporin A and intravenous immunoglobulin treatment in polymyositis/dermatomyositis. Ann Rheum Dis 61:37–34PubMedCrossRef
22.
Mitsunaka H, Tokuda M, Hiraishi T, Dobashi H, Takahara J (2000) Combined use of cyclosporin and methotrexate in refractory polymyositis. Scand J Rheumatol 29:192–194PubMedCrossRef
23.
Qushmaq KA, Chalmers A, Esdaile JM (2000) Cyclosporin A in the treatment of refractory adult polymyositis/dermatomyositis: population based experience in 6 patients and literature review. J Rheumatol 27:2855–2859PubMed
24.
Tellus MM, Buchanan RR (1997) Effective treatment of anti-Jo1 antibody positive polymyositis with cyclosporin. Br J Rheumatol 12:1187–1188
25.
Tanaka F, Origuchi T, Migita K, Tominaga M, Kawakami A, Kawabe Y, Eguchi K (2000) Successful combined therapy of cyclophosphamide and cyclosporin for acute exacerbated interstitial pneumonia associated with dermatomyositis. Intern Med 5:428–430
26.
Kameda H, Nagasawa H, Ogawa H, Sekiguchi N, Takei H, Tokuhira M, Amano K, Takeuchi T (2005) Combination therapy with corticosteroids, cyclosporin A, and intravenous pulse cyclophosphamide for acute/subacute interstitial pneumonia in patients with dermatomyositis. J Rheumatol 9:1719–1726
27.
Nawata Y, Kurasawa K, Takabayashi K, Miike S, Watanabe N, Hiraguri M, Kita Y, Kawai M, Saito Y, Iwamoto I (1999) Corticosteroid resistant interstitial pneumonitis in dermatomyositis/polymyositis: prediction and treatment with cyclosporin. J Rheumatol 7:1527–1533
28.
Shimojima Y, Ishii W, Kato T, Hoshi K, Matsuda M, Hashimoto T, Tanaka Y, Ikeda S (2003) Intractable skin necrosis and interstitial pneumonia in amyopathic dermatomyositis, successfully treated with cyclosporin A. Intern Med 12:1253–1258
29.
Dawson JK, Abernethy VE, Lynch MP (1996) Effective treatment of anti Jo-1 antibody-positive polymyositis with cyclosporin. Br J Rheumatol 1:144–145
30.
Chang HK, Lee DH (2003) Successful combination therapy of cyclosporin and methotrexate for refractory polymyositis with anti-Jo1 antibody. J Korean Med Sci 18:131–134PubMed
31.
Miller FW, Leitman SF, Cronin ME, Hicks JE, Leff RL, Wesley R (1992) Controlled trial of plasma exchange and leukapheresis in polymyositis and dermatomyositis. N Engl J Med 21:1380–1384CrossRef
32.
Cuturic M, Hayat GR, Volger CA, Velasques A (1997) Toxoplasmic polymyositis revisited: case report and review of literature. Neuromuscul Disord 7:390–396PubMedCrossRef
33.
Adams EM, Hafiz GR, Carnes M, Wiesner JK, Grabiano FM (1984) The development of polymyositis in a patient with toxoplasmosis: clinical and pathologic findings and review of literature. Clin Exp Rheumatol 3:205–208
34.
Yukiiri K, Mizushige K, Ueda T, Nanba T, Tanimoto K, Wada Y, Takagi Y, Ohmori K, Kohno M (2001) Fulminant myocarditis in polymyositis. Jpn Circ J11:991–993CrossRef
35.
Afzal A, Higgins RSD, Philbin EF (1999) Heart transplant for dilated cardiomyopathy associated with polymyositis. Heart 82:e4PubMed
Metadata
Title
Beneficial effect of treatment with cyclosporin A in a case of refractory antisynthetase syndrome
Authors
Magdalena Jankowska
Barbara Butto
Alicja Dębska-Ślizień
Bolesław Rutkowski
Publication date
01-06-2007
Publisher
Springer-Verlag
Published in
Rheumatology International / Issue 8/2007
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-006-0289-y

Other articles of this Issue 8/2007

Rheumatology International 8/2007 Go to the issue

Letter to the Editor

The CTLA-4 −1661A/G and −1772T/C dimorphisms in Japanese patients with systemic sclerosis

Original Article

Factors affecting drug treatment compliance in patients with rheumatoid arthritis

Orignal Article

Is the CD14 C159T polymorphism effective in the development of secondary amyloidosis in Familial Mediterranean fever?

Original Article

Radiation synovectomy with 90Y colloid in the therapy of recurrent knee joint effusions in patients with inflammatory joint diseases

Original Article

Use of the European preliminary criteria, the Breiman-classification tree and the American–European criteria for diagnosis of primary Sjögren’s Syndrome in daily practice: a retrospective analysis

Original Article

Long-term benefit of radon spa therapy in the rehabilitation of rheumatoid arthritis: a randomised, double-blinded trial
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits